A randomized, double-blind Phase 3 study of S-474474 in patients with essential hypertension, - Evaluation in non-responder to irbesartan
Phase 3
- Conditions
- Hypertension
- Registration Number
- JPRN-jRCT2080221107
- Lead Sponsor
- SHIONOGI & CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with essential hypertension who meet the following criteria:
Seated trough systolic blood pressure is not less than140 mmHg, lower than180 mmHg,and seated trough diastolic blood pressure is not less than 90 mmHg, lower than 110 mmHg. etc.
Exclusion Criteria
Patients with renal, hepatic or heart disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in trough seated diastolic blood pressure
- Secondary Outcome Measures
Name Time Method Adverse events and adverse drug reactions, etc